Article
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
European journal of cancer (Oxford, England : 1990) - 1 Jun 2011
Adelstein Barbara-Ann, Dobbins Timothy A, Harris Carole A, Marschner Ian C, Ward Robyn L
Abstract excerpt
BACKGROUND: In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not currently recommended for individuals with KRAS mutant tumours. This is based on subgroup analyses of individual clinical trials rather than a formal synthesis of evidence for KRAS status as a predictive biomarker, while newer trials report no benefit for anti-EGFR antibodies irrespective of KRAS status. This study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.